Future studies aiming to generate novel combinatorial CAR constructs, to increase CD70 expression density on leukemia cell surface, or to improve the persistence of CD70-CAR-T cells in vivo will be needed to optimize CAR T cell responses for AML. This evidence concerns the gene CD70 and leukemia.